Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-269.42%
operating margin TTM
-229.67%
revenue TTM
714.33 Thousand
revenue per share TTM
0.08$
valuation ratios | |
|---|---|
| pe ratio | -8.05 |
| peg ratio | 0.05 |
| price to book ratio | -3.86 |
| price to sales ratio | 13.82 |
| enterprise value multiple | -5.78 |
| price fair value | -3.86 |
profitability ratios | |
|---|---|
| gross profit margin | 91.38% |
| operating profit margin | -229.67% |
| pretax profit margin | -268.95% |
| net profit margin | -269.42% |
| return on assets | -79.38% |
| return on equity | 44.67% |
| return on capital employed | -100.35% |
liquidity ratios | |
|---|---|
| current ratio | 1.98 |
| quick ratio | 1.98 |
| cash ratio | 0.47 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 18.74 |
| days of payables outstanding | 563.22 |
| cash conversion cycle | -544.48 |
| receivables turnover | 19.48 |
| payables turnover | 0.65 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.47 |
| debt equity ratio | -0.27 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | -0.36 |
| interest coverage | -5.04 |
| cash flow to debt ratio | -2.22 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.46 |
| cash per share | 0.66 |
| operating cash flow per share | -1.46 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -2.22 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time Atara Biotherapeutics, Inc. (NASDAQ:ATRA) reported earnings?
Atara Biotherapeutics, Inc. (ATRA) published its most recent earnings results on 12-08-2026.
What is Atara Biotherapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Atara Biotherapeutics, Inc. (NASDAQ:ATRA)'s trailing twelve months ROE is 44.67%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Atara Biotherapeutics, Inc. (ATRA) currently has a ROA of -79.38%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ATRA's net profit margin stand at?
ATRA reported a profit margin of -269.42% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ATRA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.98 in the most recent quarter. The quick ratio stood at 1.98, with a Debt/Eq ratio of -0.27.